Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Apr;48(4):571–577. doi: 10.1136/gut.48.4.571

Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs

S NUGENT 1, D KUMAR 1, D RAMPTON 1, D EVANS 1
PMCID: PMC1728243  PMID: 11247905

Abstract

D S RAMPTON, D F EVANS

Gastrointestinal Science Research Unit
Royal London Hospital, London, UK


Measurements of luminal pH in the normal gastrointestinal tract have shown a progressive increase in pH from the duodenum to the terminal ileum, a decrease in the caecum, and then a slow rise along the colon to the rectum. Some data in patients with ulcerative colitis suggest a substantial reduction below normal values in the right colon, while limited results in Crohn's disease have been contradictory. Determinants of luminal pH in the colon include mucosal bicarbonate and lactate production, bacterial fermentation of carbohydrates and mucosal absorption of short chain fatty acids, and possibly intestinal transit. Alterations in these factors, as a result of mucosal disease and changes in diet, are likely to explain abnormal pH measurements in inflammatory bowel disease (IBD). It is conceivable that reduced intracolonic pH in active ulcerative colitis impairs bioavailability of 5-aminosalicylic acid from pH dependent release formulations (Asacol, Salofalk) and those requiring cleavage by bacterial azo reductase (sulphasalazine, olsalazine, balsalazide), but further pharmacokinetic studies are needed to confirm this possibility. Reports that balsalazide and olsalazine may be more efficacious in active and quiescent ulcerative colitis, respectively, than Asacol suggest that low pH may be a more critical factor in patients taking directly pH dependent release than azo bonded preparations. Reduced intracolonic pH also needs to be considered in the development of pH dependent colonic release formulations of budesonide and azathioprine for use in ulcerative and Crohn's colitis. This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies.



Full Text

The Full Text of this article is available as a PDF (157.3 KB).

graphic file with name gut-medm.f1.jpg

Open in a new tab

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan E. S., Winter S., Light A. M., Allan A. Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. Gut. 1996 Jun;38(6):886–893. doi: 10.1136/gut.38.6.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allgayer H., Ahnfelt N. O., Kruis W., Klotz U., Frank-Holmberg K., Söderberg H. N., Paumgartner G. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989 Jul;97(1):38–41. doi: 10.1016/0016-5085(89)91412-1. [DOI] [PubMed] [Google Scholar]
  3. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  4. Bar-Meir S., Chowers Y., Lavy A., Abramovitch D., Sternberg A., Leichtmann G., Reshef R., Odes S., Moshkovitz M., Bruck R. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 1998 Oct;115(4):835–840. doi: 10.1016/s0016-5085(98)70254-9. [DOI] [PubMed] [Google Scholar]
  5. Bown R. L., Gibson J. A., Sladen G. E., Hicks B., Dawson A. M. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974 Dec;15(12):999–1004. doi: 10.1136/gut.15.12.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cammà C., Giunta M., Rosselli M., Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997 Nov;113(5):1465–1473. doi: 10.1053/gast.1997.v113.pm9352848. [DOI] [PubMed] [Google Scholar]
  7. Caprilli R., Frieri G., Latella G., Vernia P., Santoro M. L. Faecal excretion of bicarbonate in ulcerative colitis. Digestion. 1986;35(3):136–142. doi: 10.1159/000199359. [DOI] [PubMed] [Google Scholar]
  8. Chapman M. A., Grahn M. F., Boyle M. A., Hutton M., Rogers J., Williams N. S. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994 Jan;35(1):73–76. doi: 10.1136/gut.35.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Christensen L. A., Fallingborg J., Abildgaard K., Jacobsen B. A., Sanchez G., Hansen S. H., Bondesen S., Hvidberg E. F., Rasmussen S. N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. doi: 10.1111/j.1365-2036.1990.tb00499.x. [DOI] [PubMed] [Google Scholar]
  10. Christensen L. A., Fallingborg J., Jacobsen B. A., Abildgaard K., Rasmussen H. H., Hansen S. H., Rasmussen S. N. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther. 1994 Jun;8(3):289–294. doi: 10.1111/j.1365-2036.1994.tb00290.x. [DOI] [PubMed] [Google Scholar]
  11. Christensen L. A., Slot O., Sanchez G., Boserup J., Rasmussen S. N., Bondesen S., Hansen S. H., Hvidberg E. F. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol. 1987 Mar;23(3):365–369. doi: 10.1111/j.1365-2125.1987.tb03061.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Colson R. H., Watson B. W., Fairclough P. D., Walker-Smith J. A., Campbell C. A., Bellamy D., Hinsull S. M. An accurate, long-term, pH-sensitive radio pill for ingestion and implantation. Biotelem Patient Monit. 1981;8(4):213–227. [PubMed] [Google Scholar]
  13. Courtney M. G., Nunes D. P., Bergin C. F., O'Driscoll M., Trimble V., Keeling P. W., Weir D. G. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet. 1992 May 23;339(8804):1279–1281. doi: 10.1016/0140-6736(92)91601-4. [DOI] [PubMed] [Google Scholar]
  14. Cummings J. H., Hill M. J., Bone E. S., Branch W. J., Jenkins D. J. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr. 1979 Oct;32(10):2094–2101. doi: 10.1093/ajcn/32.10.2094. [DOI] [PubMed] [Google Scholar]
  15. Dew M. J., Ryder R. E., Evans N., Evans B. K., Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983 Aug;16(2):185–187. doi: 10.1111/j.1365-2125.1983.tb04983.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Down P. F., Agostini L., Murison J., Wrong O. M. The interrelations of faecal ammonia, pH and bicarbonate: evidence of colonic absorption of ammonia by non-ionic diffusion. Clin Sci. 1972 Jul;43(1):101–114. doi: 10.1042/cs0430101. [DOI] [PubMed] [Google Scholar]
  17. Evans D. F., Pye G., Bramley R., Clark A. G., Dyson T. J., Hardcastle J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988 Aug;29(8):1035–1041. doi: 10.1136/gut.29.8.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ewe K., Schwartz S., Petersen S., Press A. G. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci. 1999 Jul;44(7):1434–1439. doi: 10.1023/a:1026664105112. [DOI] [PubMed] [Google Scholar]
  19. Faegenburg D., Kryle L. S., Kashiwabara H., Doctor N. M., Pai P. Intestinal obstruction caused by ingestion of a Heidelberg capsule: report of a case. Am J Gastroenterol. 1985 Oct;80(10):787–789. [PubMed] [Google Scholar]
  20. Fallingborg J., Christensen L. A., Ingeman-Nielsen M., Jacobsen B. A., Abildgaard K., Rasmussen H. H. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989 Dec;3(6):605–613. doi: 10.1111/j.1365-2036.1989.tb00254.x. [DOI] [PubMed] [Google Scholar]
  21. Fallingborg J., Christensen L. A., Jacobsen B. A., Rasmussen S. N. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci. 1993 Nov;38(11):1989–1993. doi: 10.1007/BF01297074. [DOI] [PubMed] [Google Scholar]
  22. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999 Jun;46(3):183–196. [PubMed] [Google Scholar]
  23. Fallingborg J., Pedersen P., Jacobsen B. A. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease. Dig Dis Sci. 1998 Apr;43(4):702–705. doi: 10.1023/a:1018893409596. [DOI] [PubMed] [Google Scholar]
  24. Finnie I. A., Taylor B. A., Rhodes J. M. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut. 1993 Nov;34(11):1552–1558. doi: 10.1136/gut.34.11.1552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Frieri G., Pimpo M. T., Andreoli A., Annese V., Comberlato M., Corrao G., Palumbo G., Sturniolo G. C., Tonelli F., Caprilli R. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. Aliment Pharmacol Ther. 1999 May;13(5):577–582. doi: 10.1046/j.1365-2036.1999.00501.x. [DOI] [PubMed] [Google Scholar]
  26. Green J. R., Gibson J. A., Kerr G. D., Swarbrick E. T., Lobo A. J., Holdsworth C. D., Crowe J. P., Schofield K. J., Taylor M. D. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther. 1998 Dec;12(12):1207–1216. doi: 10.1046/j.1365-2036.1998.00427.x. [DOI] [PubMed] [Google Scholar]
  27. Green J. R., Lobo A. J., Holdsworth C. D., Leicester R. J., Gibson J. A., Kerr G. D., Hodgson H. J., Parkins K. J., Taylor M. D. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998 Jan;114(1):15–22. doi: 10.1016/s0016-5085(98)70627-4. [DOI] [PubMed] [Google Scholar]
  28. Greenfield S. M., Punchard N. A., Teare J. P., Thompson R. P. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993 Aug;7(4):369–383. doi: 10.1111/j.1365-2036.1993.tb00110.x. [DOI] [PubMed] [Google Scholar]
  29. Hove H., Holtug K., Jeppesen P. B., Mortensen P. B. Butyrate absorption and lactate secretion in ulcerative colitis. Dis Colon Rectum. 1995 May;38(5):519–525. doi: 10.1007/BF02148853. [DOI] [PubMed] [Google Scholar]
  30. Hove H., Mortensen P. B. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. Dig Dis Sci. 1995 Jun;40(6):1372–1380. doi: 10.1007/BF02065554. [DOI] [PubMed] [Google Scholar]
  31. Jalan K. N., Walker R. J., Prescott R. J., Butterworth S. T., Smith A. N., Sircus W. Faecal stasis and diverticular disease in ulcerative colitis. Gut. 1970 Aug;11(8):688–696. doi: 10.1136/gut.11.8.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lennard-Jones J. E., Langman M. J., Jones F. A. Faecal stasis in proctocolitis. Gut. 1962 Dec;3(4):301–305. doi: 10.1136/gut.3.4.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Manousos O. N., Salem S. N. Abnormal motility of the small intestine in ulcerative colitis. Gastroenterologia. 1965;104(4):249–257. doi: 10.1159/000202102. [DOI] [PubMed] [Google Scholar]
  34. Mardini H. A., Lindsay D. C., Deighton C. M., Record C. O. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987 Sep;28(9):1084–1089. doi: 10.1136/gut.28.9.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McDougall C. J., Wong R., Scudera P., Lesser M., DeCosse J. J. Colonic mucosal pH in humans. Dig Dis Sci. 1993 Mar;38(3):542–545. doi: 10.1007/BF01316512. [DOI] [PubMed] [Google Scholar]
  36. McNeil N. I., Ling K. L., Wager J. Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man. Gut. 1987 Jun;28(6):707–713. doi: 10.1136/gut.28.6.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Myers B., Evans D. N., Rhodes J., Evans B. K., Hughes B. R., Lee M. G., Richens A., Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987 Feb;28(2):196–200. doi: 10.1136/gut.28.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Nolen H., 3rd, Fedorak R. N., Friend D. R. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci. 1995 Jun;84(6):677–681. doi: 10.1002/jps.2600840603. [DOI] [PubMed] [Google Scholar]
  39. Pearson D. C., May G. R., Fick G. H., Sutherland L. R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995 Jul 15;123(2):132–142. doi: 10.7326/0003-4819-123-2-199507150-00009. [DOI] [PubMed] [Google Scholar]
  40. Press A. G., Hauptmann I. A., Hauptmann L., Fuchs B., Fuchs M., Ewe K., Ramadori G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1998 Jul;12(7):673–678. doi: 10.1046/j.1365-2036.1998.00358.x. [DOI] [PubMed] [Google Scholar]
  41. Rao S. S., Read N. W., Brown C., Bruce C., Holdsworth C. D. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987 Nov;93(5):934–940. doi: 10.1016/0016-5085(87)90554-3. [DOI] [PubMed] [Google Scholar]
  42. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  43. Reddy S. N., Bazzocchi G., Chan S., Akashi K., Villanueva-Meyer J., Yanni G., Mena I., Snape W. J., Jr Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991 Nov;101(5):1289–1297. doi: 10.1016/0016-5085(91)90079-z. [DOI] [PubMed] [Google Scholar]
  44. Rijk M. C., van Hogezand R. A., van Schaik A., van Tongeren J. H. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol. 1989 Dec;24(10):1179–1185. doi: 10.3109/00365528909090784. [DOI] [PubMed] [Google Scholar]
  45. Rijk M. C., van Schaik A., van Tongeren J. H. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol. 1992 Oct;27(10):863–868. doi: 10.3109/00365529209000155. [DOI] [PubMed] [Google Scholar]
  46. Riley S. A., Tavares I. A., Bennett A., Mani V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988 Aug;26(2):173–177. doi: 10.1111/j.1365-2125.1988.tb03383.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ritchie J. A., Salem S. N. Upper intestinal motility in ulcerative colitis, idiopathic steatorrhoea, and the irritable colon syndrome. Gut. 1965 Aug;6(4):325–337. doi: 10.1136/gut.6.4.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Roediger W. E., Heyworth M., Willoughby P., Piris J., Moore A., Truelove S. C. Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. J Clin Pathol. 1982 Mar;35(3):323–326. doi: 10.1136/jcp.35.3.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Roediger W. E., Lawson M. J., Kwok V., Grant A. K., Pannall P. R. Colonic bicarbonate output as a test of disease activity in ulcerative colitis. J Clin Pathol. 1984 Jun;37(6):704–707. doi: 10.1136/jcp.37.6.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Roediger W. E. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980 Oct 4;2(8197):712–715. doi: 10.1016/s0140-6736(80)91934-0. [DOI] [PubMed] [Google Scholar]
  51. Rubinstein R., Howard A. V., Wrong O. M. In vivo dialysis of faeces as a method of stool analysis. IV. The organic anion component. Clin Sci. 1969 Oct;37(2):549–564. [PubMed] [Google Scholar]
  52. Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., Danielsson A., Goebell H., Thomsen O. O., Lorenz-Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331(13):842–845. doi: 10.1056/NEJM199409293311304. [DOI] [PubMed] [Google Scholar]
  53. Sasaki Y., Hada R., Nakajima H., Fukuda S., Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol. 1997 Jan;92(1):114–118. [PubMed] [Google Scholar]
  54. Singleton J. W., Hanauer S. B., Gitnick G. L., Peppercorn M. A., Robinson M. G., Wruble L. D., Krawitt E. L. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May;104(5):1293–1301. doi: 10.1016/0016-5085(93)90337-c. [DOI] [PubMed] [Google Scholar]
  55. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. doi: 10.7326/0003-4819-118-7-199304010-00009. [DOI] [PubMed] [Google Scholar]
  57. TRUELOVE S. C., WATKINSON G., DRAPER G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962 Dec 29;2(5321):1708–1711. doi: 10.1136/bmj.2.5321.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Thomsen O. O., Cortot A., Jewell D., Wright J. P., Winter T., Veloso F. T., Vatn M., Persson T., Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998 Aug 6;339(6):370–374. doi: 10.1056/NEJM199808063390603. [DOI] [PubMed] [Google Scholar]
  59. Travis S. P., Jewell D. P. Salicylates for inflammatory bowel disease. Baillieres Clin Gastroenterol. 1994 Jun;8(2):203–231. doi: 10.1016/0950-3528(94)90002-7. [DOI] [PubMed] [Google Scholar]
  60. Tremaine W. J., Schroeder K. W., Harrison J. M., Zinsmeister A. R. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994 Dec;19(4):278–282. doi: 10.1097/00004836-199412000-00003. [DOI] [PubMed] [Google Scholar]
  61. Vernia P., Caprilli R., Latella G., Barbetti F., Magliocca F. M., Cittadini M. Fecal lactate and ulcerative colitis. Gastroenterology. 1988 Dec;95(6):1564–1568. doi: 10.1016/s0016-5085(88)80078-7. [DOI] [PubMed] [Google Scholar]
  62. Watson B. W., Meldrum S. J., Riddle H. C., Brown R. L., Sladen G. E. pH profile of gut as measured by radiotelemetry capsule. Br Med J. 1972 Apr 8;2(5805):104–106. doi: 10.1136/bmj.2.5805.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zins B. J., Sandborn W. J., McKinney J. A., Mays D. C., van Os E. C., Tremaine W. J., Mahoney D. W., Zinsmeister A. R., Lipsky J. J. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan;37(1):38–46. doi: 10.1177/009127009703700107. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES